IMR Press / FBL / Special Issues / 1423570489141809153

Cell death signaling: The two faces of annihilation

Submission deadline: 31 July 2022
Special Issue Editors
Rohit Gundamaraju, MD
ER stress and mucosal immunology team, School of Health Sciences, University of Tasmania
Interests: UPR; Cancers; Gut; Apoptosis; Cancer progression
Niraj Kumar Jha
Department of Biotechnology, Sharda University, Greater Noida, Uttar Pradesh-201310, India
Interests: Natural Products; Cell Signaling and Disease
Special Issue Information

Dear Colleagues,

The two principal types of programmed cell death are apoptosis and autophagy-associated cell death. The recognition that cell death can occur by genetically controlled processes has aided advances in unveiling the mechanisms of many diseases. As a result, we now have improved knowledge of the initiation of cell death programs and the relevant signaling pathways. This information has facilitated development of pharmacologic agents that initiate or inhibit programmed cell death. Moreover, there is now evidence that necrosis, traditionally considered an accidental form of cell death, can, in certain instances, be initiated or modulated under programmed control mechanisms.

Mounting evidence in the context of cell death pathways has led to development of promising novel therapies. Despite these advances, answers to a number of enigmatic and interesting questions remain. Why some cell types are much more vulnerable to ischemic cell death than most others? How does a cell select a particular type of death and execute? How does a cell switch from a stress or environmental insults recovery program to cell death? What criteria propel the alternative of cell death pathway? When is a cell committed to death? Such understandings will make us land in a profound understanding of cell death, an expanding foundation on which increasingly effective therapeutic interventions may be modeled and introduced into clinical practice in diverse diseases. The current special issue will address multi factorial approaches in the area of cell death pathways in multiple diseases.

Dr. Rohit Gundamaraju and Dr. Niraj Kumar Jha

Guest Editors

Keywords
Cell Death Pathways
Mechanisms of Apoptosis
Disease Therapeutics
Cancer
Inflammation
Cell Death Signaling
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Back to top